Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 11 of the 13 calendar months from Oct 2025 to Oct 2026: Nov 2025, Dec 2025, Feb 2026, Mar 2026, Apr 2026, May 2026, Jun 2026, Jul 2026, Aug 2026, Sep 2026 and Oct 2026.
- Largest single sale: $1.7M (15,492 shares) of Halozyme Therapeutics, Inc. on Sep 11, 2026. Filing
- Last sale before this period: Oct 3, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | President and CEO, Director | Jan 8, 2014 | Oct 8, 2026 |
| Quest Diagnostics (DGX) | Former Director | May 17, 2018 | May 25, 2021 |
Also a director at
Quest Diagnostics (DGX) (no filing in the last 18 months)
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Oct 8, 2026, Halozyme Therapeutics, Inc.: sold 20,000 shares for $2.2M, under a disclosed plan; 20,000 shares vested or acquired by exercising options. 1 filing: 1
- Oct 7, 2026, Halozyme Therapeutics, Inc.: sold 20,000 shares for $2.2M, under a disclosed plan; 20,000 shares vested or acquired by exercising options. 1 filing: 1
- Oct 6, 2026, Halozyme Therapeutics, Inc.: sold 20,000 shares for $2.2M, under a disclosed plan; 20,000 shares vested or acquired by exercising options. 1 filing: 1
- Sep 11, 2026, Halozyme Therapeutics, Inc.: sold 20,000 shares for $2.1M, under a disclosed plan; 20,000 shares vested or acquired by exercising options. 1 filing: 1
- Sep 10, 2026, Halozyme Therapeutics, Inc.: sold 20,000 shares for $2.1M, under a disclosed plan; 20,000 shares vested or acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.